Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families ...

Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...

To see if cryptic pockets were also present on other GTPases, Shokat and coworkers overlaid the sequence of these enzymes ...

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; ...

The inhibition of ERK5 is a potential complementary strategy for countering FAK inhibitor resistance in patients with lung ...